17562951|t|Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
17562951|a|BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions. Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications. The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L) over baseline. Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr. In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups. SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44). In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37). Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01). CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus. Any true difference between the agents is small and not likely to be clinically significant.
17562951	40	48	Patients	OrganismTaxon	9606
17562951	98	106	contrast	ChemicalEntity	D003287
17562951	115	126	nephropathy	DiseaseOrPhenotypicFeature	D007674
17562951	130	138	patients	OrganismTaxon	9606
17562951	144	166	chronic kidney disease	DiseaseOrPhenotypicFeature	D051436
17562951	256	271	contrast medium	ChemicalEntity	D003287
17562951	272	281	iopamidol	ChemicalEntity	D007479
17562951	314	329	contrast medium	ChemicalEntity	D003287
17562951	330	339	iodixanol	ChemicalEntity	C044834
17562951	353	361	patients	OrganismTaxon	9606
17562951	459	468	iopamidol	ChemicalEntity	D007479
17562951	473	482	iodixanol	ChemicalEntity	C044834
17562951	486	494	patients	OrganismTaxon	9606
17562951	500	522	chronic kidney disease	DiseaseOrPhenotypicFeature	D051436
17562951	659	669	creatinine	ChemicalEntity	D003404
17562951	671	674	SCr	ChemicalEntity	D003404
17562951	830	833	SCr	ChemicalEntity	D003404
17562951	928	931	SCr	ChemicalEntity	D003404
17562951	1053	1056	SCr	ChemicalEntity	D003404
17562951	1065	1073	patients	OrganismTaxon	9606
17562951	1075	1083	contrast	ChemicalEntity	D003287
17562951	1104	1121	diabetes mellitus	DiseaseOrPhenotypicFeature	D003920
17562951	1130	1146	N-acetylcysteine	ChemicalEntity	D000111
17562951	1162	1165	SCr	ChemicalEntity	D003404
17562951	1241	1244	SCr	ChemicalEntity	D003404
17562951	1299	1307	patients	OrganismTaxon	9606
17562951	1315	1324	iopamidol	ChemicalEntity	D007479
17562951	1345	1353	patients	OrganismTaxon	9606
17562951	1361	1370	iodixanol	ChemicalEntity	C044834
17562951	1398	1401	SCr	ChemicalEntity	D003404
17562951	1470	1478	patients	OrganismTaxon	9606
17562951	1484	1492	diabetes	DiseaseOrPhenotypicFeature	D003920
17562951	1494	1497	SCr	ChemicalEntity	D003404
17562951	1544	1552	patients	OrganismTaxon	9606
17562951	1559	1568	iopamidol	ChemicalEntity	D007479
17562951	1589	1597	patients	OrganismTaxon	9606
17562951	1604	1613	iodixanol	ChemicalEntity	C044834
17562951	1632	1635	SCr	ChemicalEntity	D003404
17562951	1712	1715	SCr	ChemicalEntity	D003404
17562951	1755	1764	iopamidol	ChemicalEntity	D007479
17562951	1770	1778	patients	OrganismTaxon	9606
17562951	1840	1848	patients	OrganismTaxon	9606
17562951	1854	1862	diabetes	DiseaseOrPhenotypicFeature	D003920
17562951	1950	1958	contrast	ChemicalEntity	D003287
17562951	1967	1978	nephropathy	DiseaseOrPhenotypicFeature	D007674
17562951	2085	2094	iopamidol	ChemicalEntity	D007479
17562951	2098	2107	iodixanol	ChemicalEntity	C044834
17562951	2121	2129	patients	OrganismTaxon	9606
17562951	2147	2164	diabetes mellitus	DiseaseOrPhenotypicFeature	D003920
17562951	Positive_Correlation	C044834	D007674	Novel
17562951	Comparison	D007479	C044834	Novel
17562951	Positive_Correlation	D007479	D007674	Novel
17562951	Positive_Correlation	D003404	C044834	Novel
17562951	Positive_Correlation	D003404	D007479	Novel
17562951	Positive_Correlation	D003287	D007674	No